Compare Stocks: MNPR, PHVS, VERA, and LKFT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LKFT Lakefront Biotherapeutics American Depositary Shares	$29.40 +1.2%	$28.68	$25.68 ▼ $36.24	$1.91B	0.24	344,931 shs	226,585 shs
MNPR Monopar Therapeutics	$73.10 +1.4%	$101.80	$50.07 ▼ $124.82	$483.81M	1.5	174,523 shs	129,633 shs
PHVS Pharvaris	$30.02	$34.72	$20.65 ▼ $43.25	$1.96B	-2.46	684,894 shs	400,420 shs
VERA Vera Therapeutics	$26.74 -0.2%	$32.52	$23.05 ▼ $56.05	$1.93B	1.06	2.15 million shs	1.53 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LKFT Lakefront Biotherapeutics American Depositary Shares	-1.76%	-0.92%	+8.36%	-1.46%	-14.36%
MNPR Monopar Therapeutics	-6.45%	-9.41%	-34.63%	-33.68%	-29.37%
PHVS Pharvaris	-2.82%	-3.53%	-21.04%	-14.62%	+36.02%
VERA Vera Therapeutics	-3.35%	-8.94%	-23.57%	-36.96%	-12.14%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LKFT Lakefront Biotherapeutics American Depositary Shares	$29.40 +1.2%	$28.68	$25.68 ▼ $36.24	$1.91B	0.24	344,931 shs	226,585 shs
MNPR Monopar Therapeutics	$73.10 +1.4%	$101.80	$50.07 ▼ $124.82	$483.81M	1.5	174,523 shs	129,633 shs
PHVS Pharvaris	$30.02	$34.72	$20.65 ▼ $43.25	$1.96B	-2.46	684,894 shs	400,420 shs
VERA Vera Therapeutics	$26.74 -0.2%	$32.52	$23.05 ▼ $56.05	$1.93B	1.06	2.15 million shs	1.53 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LKFT Lakefront Biotherapeutics American Depositary Shares	-1.76%	-0.92%	+8.36%	-1.46%	-14.36%
MNPR Monopar Therapeutics	-6.45%	-9.41%	-34.63%	-33.68%	-29.37%
PHVS Pharvaris	-2.82%	-3.53%	-21.04%	-14.62%	+36.02%
VERA Vera Therapeutics	-3.35%	-8.94%	-23.57%	-36.96%	-12.14%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LKFT Lakefront Biotherapeutics American Depositary Shares	2.56	Moderate Buy	$37.00	25.85% Upside
MNPR Monopar Therapeutics	2.70	Moderate Buy	$122.00	66.89% Upside
PHVS Pharvaris	2.80	Moderate Buy	$58.60	95.20% Upside
VERA Vera Therapeutics	2.80	Moderate Buy	$76.86	187.42% Upside

Current Analyst Ratings Breakdown

Latest MNPR, PHVS, VERA, and LKFT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/12/2026	VERA Vera Therapeutics	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Market Perform	$34.00
10/6/2026	PHVS Pharvaris	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$60.00
10/6/2026	PHVS Pharvaris	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/2/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C-) ➝ Hold (C)
9/23/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Buy
9/23/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sector Perform ➝ Outperform	$26.00 ➝ $45.00
9/16/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold (C) ➝ Hold (C-)
9/15/2026	VERA Vera Therapeutics	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/15/2026	VERA Vera Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Strong-Buy
9/14/2026	PHVS Pharvaris	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight	$65.00
9/11/2026	MNPR Monopar Therapeutics	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight	$128.00 ➝ $145.00

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LKFT Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.54	$0.73 per share	40.01	$47.57 per share	0.62
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$20.62 per share	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	$4.71 per share	N/A
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	$8.48 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LKFT Lakefront Biotherapeutics American Depositary Shares	$363.05M	-$1.41	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	-$13.72M	-$2.17	N/A	N/A	N/A	N/A	-13.08%	-12.79%	11/12/2026 (Estimated)
PHVS Pharvaris	-$198.79M	-$3.05	N/A	N/A	N/A	N/A	-61.40%	-56.00%	11/11/2026 (Estimated)
VERA Vera Therapeutics	-$299.61M	-$5.86	N/A	N/A	N/A	N/A	-84.13%	-66.79%	11/4/2026 (Estimated)

Latest MNPR, PHVS, VERA, and LKFT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	PHVS Pharvaris	-$0.82	N/A	N/A	N/A	$2.35 million	N/A
11/4/2026	Q3 2026	VERA Vera Therapeutics	-$1.61	N/A	N/A	N/A	$3.90 million	N/A
8/12/2026	Q2 2026	MNPR Monopar Therapeutics	-$0.6425	-$0.62	+$0.0225	-$0.7920	N/A	N/A
8/12/2026	Q2 2026	PHVS Pharvaris	-$0.7467	-$0.81	-$0.0633	-$0.80	N/A	N/A
8/10/2026	Q2 2026	LKFT Lakefront Biotherapeutics American Depositary Shares	-$0.9672	$0.03	+$0.9972	$0.0330	$7.29 million	$15.47 million
8/10/2026	Q2 2026	VERA Vera Therapeutics	-$1.58	-$1.52	+$0.06	-$1.52	$1.28 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
LKFT Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LKFT Lakefront Biotherapeutics American Depositary Shares	N/A	32.84	32.72
MNPR Monopar Therapeutics	N/A	33.56	33.56
PHVS Pharvaris	N/A	11.94	11.94
VERA Vera Therapeutics	0.18	10.92	10.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LKFT Lakefront Biotherapeutics American Depositary Shares	32.46%
MNPR Monopar Therapeutics	1.83%
PHVS Pharvaris	N/A
VERA Vera Therapeutics	99.21%

Insider Ownership

Company	Insider Ownership
LKFT Lakefront Biotherapeutics American Depositary Shares	2.91%
MNPR Monopar Therapeutics	9.70%
PHVS Pharvaris	11.84%
VERA Vera Therapeutics	15.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LKFT Lakefront Biotherapeutics American Depositary Shares	1,310	65.90 million	63.98 million	Optionable
MNPR Monopar Therapeutics	22	6.71 million	6.06 million	Not Optionable
PHVS Pharvaris	148	65.41 million	57.66 million	Not Optionable
VERA Vera Therapeutics	361	72.06 million	60.61 million	Optionable

MNPR, PHVS, VERA, and LKFT Headlines

Recent News About These Companies

Can Vera Therapeutics Stage Another Comeback?

October 14 at 12:50 PM | rttnews.com

Leerink Partners initiates coverage of Vera Therapeutics at market perform

October 13 at 2:58 PM | msn.com

Leerink Partners Initiates Vera Therapeutics at Market Perform With $34 Price Target

October 13 at 2:58 PM | finance.yahoo.com

Vera Therapeutics, Inc. (VERA) Stock Analysis: Unveiling a Potential 167% Upside in the Biotechnology Sector

October 13 at 2:58 PM | directorstalkinterviews.com

Vera Therapeutics (NASDAQ:VERA) Now Covered by Leerink Partners

October 12 at 8:42 AM | americanbankingnews.com

Leerink Partners Begins Coverage on Vera Therapeutics (NASDAQ:VERA)

October 12 at 8:41 AM | marketbeat.com

BofA Securities Adjusts Vera Therapeutics Price Target to $60 From $66, Maintains Buy Rating

October 9, 2026 | finance.yahoo.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Stock Has Consensus Target Price of $80.15

October 8, 2026 | americanbankingnews.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Stock Has Consensus Price Target of $80.15

October 8, 2026 | marketbeat.com

Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ...

October 5, 2026 | marketscreener.comM

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 2, 2026

October 5, 2026 | biospace.comB

Vera Therapeutics Announces Origin 3 Final Efficacy Analysis of TRUTAKNA in Iga Nephropathy Will Be A Featured Late-Breaking Oral Presentation At Asn Kidney Week 2026

October 3, 2026 | marketscreener.comM

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 2, 2026 | globenewswire.com

Vera Therapeutics to present ORIGIN 3 trial data at ASN Kidney Week

October 2, 2026 | streetinsider.com

Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the ...

October 2, 2026 | finance.yahoo.com

Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026

October 2, 2026 | globenewswire.com

Vera Therapeutics (NASDAQ:VERA) Shares Down 8.3% - Here's What Happened

September 23, 2026 | marketbeat.com

Insider Selling: Vera Therapeutics (NASDAQ:VERA) CEO Sells 18,500 Shares of Stock

September 18, 2026 | insidertrades.com

Analysts Offer Insights on Healthcare Companies: Viatris (VTRS) and Vera Therapeutics (VERA)

September 17, 2026 | theglobeandmail.com

Marshall Fordyce Sells 18,500 Shares of Vera Therapeutics (NASDAQ:VERA) Stock

September 17, 2026 | marketbeat.com

Vera Therapeutics (NASDAQ:VERA) Shares Up 7.8% - What's Next?

September 17, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MNPR, PHVS, VERA, and LKFT Company Descriptions

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

$29.40 +0.35 (+1.20%)

As of 04:00 PM Eastern

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Monopar Therapeutics NASDAQ:MNPR

$73.10 +1.02 (+1.42%)

Closing price 04:00 PM Eastern

Extended Trading

$73.13 +0.03 (+0.04%)

As of 07:50 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Pharvaris NASDAQ:PHVS

$30.02 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$30.03 +0.01 (+0.03%)

As of 07:30 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

Vera Therapeutics NASDAQ:VERA

$26.74 -0.05 (-0.19%)

Closing price 04:00 PM Eastern

Extended Trading

$26.73 -0.01 (-0.04%)

As of 07:45 PM Eastern

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MNPR, PHVS, VERA, and LKFT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MNPR, PHVS, VERA, and LKFT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MNPR, PHVS, VERA, and LKFT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MNPR, PHVS, VERA, and LKFT Company Descriptions

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

Monopar Therapeutics NASDAQ:MNPR

Pharvaris NASDAQ:PHVS

Vera Therapeutics NASDAQ:VERA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MNPR, PHVS, VERA, and LKFT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MNPR, PHVS, VERA, and LKFT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MNPR, PHVS, VERA, and LKFT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MNPR, PHVS, VERA, and LKFT Company Descriptions

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

Monopar Therapeutics NASDAQ:MNPR

Pharvaris NASDAQ:PHVS

Vera Therapeutics NASDAQ:VERA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools